The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer

Gastric Cancer, Metastatic Clinical Trial

Official title:
Prospective Randomized Phase II Clinical Trial: the Efficacy of Surgical Treatment in Combinations With Intraperitoneal Immunotherapy and Systemic Chemotherapy in Patients With Gastric Cancer and Verified Free Cancer Cells

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine whether intraperitoneal immunotherapy (with interleykin-2 - human cytokine reaction activator) with systemic chemotherapy will be more effective than systemic chemotherapy alone in patients with gastric cancer and verified free cancer cells in abdominal cavity in improving the long term outcomes and overall survival of further surgical treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02976142
Study type	Interventional
Source	Moscow Clinical Scientific Center
Contact	Igor Khatkov, Professor, PhD
Email	i.hatkov@mknc.ru
Status	Not yet recruiting
Phase	Phase 2
Start date	December 2016
Completion date	December 2020

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06427252` - The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM	Phase 2
	Not yet recruiting	`NCT06283121` - A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer	Phase 2